미국의 고용주 및 직장용 약물 검사 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 모드별, 약물별, 최종 용도별, 부문별 예측(2025-2033년)

Market Size & Trends:

The U.S. employer and workplace drug testing market size was estimated at USD 2.57 billion in 2024 and is projected to reach USD 4.01 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. The market is primarily driven by stringent workplace safety regulations, growing awareness of substance abuse risks, and the increasing adoption of preventive screening measures across various industries. Drug testing programs are widely implemented to detect the presence of illicit substances and misuse of prescription medications, while comprehensive screening protocols support compliance with federal and state requirements, promote productivity, and reduce workplace incidents.

The demand for pre-employment and random workplace testing is growing, supported by improvements in rapid testing kits, lab-based tests, and oral fluid testing methods. Digital result systems and automated reporting have made the process faster and more accurate, helping employers make quick hiring decisions and monitor staff more effectively. Changing cannabis laws in several states are also leading companies to adjust their testing policies to meet both compliance needs and evolving legal standards.

A national survey by American Addiction Centers in 2024 found that 15.3% of U.S. workers had worked under the influence of alcohol, while 2.9% admitted to being under the influence of illegal drugs. This shows the ongoing challenges faced by employers and highlights the need for strong drug testing policies to protect workplace safety and productivity.

The rising number of employees with substance use disorders (SUD) further increases the importance of workplace testing. Substance abuse can lead to lower productivity, more absenteeism, and higher rates of illness. It also harms employee morale and raises the risk of workplace accidents and injuries, which together cost U.S. businesses billions of dollars each year. These factors are expected to keep driving the demand for employer and workplace drug testing services across the country.

Overall, the U.S. employer and workplace drug testing market is experiencing steady innovation aimed at improving speed, accuracy, and ease of use. Advancements in testing methods, digital result management, and analytical tools are helping employers streamline screening processes while ensuring compliance with evolving regulations. The adoption of multi-panel and oral fluid testing, supported by cloud-based platforms and AI-driven analytics, is making it easier to detect a broader range of substances and identify potential issues early. These innovations are expected to strengthen workplace safety programs and support more effective workforce management in the years ahead.

U.S. Employer And Workplace Drug Testing Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. employer and workplace drug testing market on type, product, mode, drug and end-use:

• Type Outlook (Revenue in USD Million, 2021 - 2033)
• Pre-employment Drug Screens
• Post-employment
• Product Outlook (Revenue in USD Million, 2021 - 2033)
• Consumables
• Instruments
• Rapid Testing Devices
• Services
• Mode Outlook (Revenue in USD Million, 2021 - 2033)
• Consumables
• Instruments
• Rapid Testing Devices
• Services
• Drug Outlook (Revenue in USD Million, 2021 - 2033)
• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• Others
• End-use Outlook (Revenue in USD Million, 2021 - 2033)
• IT/Finance
• Manufacturing
• Transportation
• Construction
• Retail and Hospitality
• Healthcare
• Education
• Other Professional Services

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Product Segment
  • 1.2.3. Mode Segment
  • 1.2.4. Drug Segment
  • 1.2.5. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. U.S. Employer and Workplace Drug Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Employer and Workplace Drug Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Employer and Workplace Drug Testing Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Employer and Workplace Drug Testing Market Type Movement Analysis
• 4.3. U.S. Employer and Workplace Drug Testing Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Pre-employment Drug Screens
  • 4.4.1. Pre-employment drug screens market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Post-employment
  • 4.5.1. Post-employment market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Employer and Workplace Drug Testing Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Employer and Workplace Drug Testing Market Product Movement Analysis
• 5.3. U.S. Employer and Workplace Drug Testing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Rapid Testing Devices
  • 5.6.1. Rapid testing devices market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Services
  • 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Employer and Workplace Drug Testing Market: Mode Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Employer and Workplace Drug Testing Market Mode Movement Analysis
• 6.3. U.S. Employer and Workplace Drug Testing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
• 6.4. Urine
  • 6.4.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Hair
  • 6.5.1. Hair market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Oral Fluid
  • 6.6.1. Oral fluid market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Instant testing
  • 6.7.1. Instant testing market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Employer and Workplace Drug Testing Market: Drug Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Employer and Workplace Drug Testing Market Drug Movement Analysis
• 7.3. U.S. Employer and Workplace Drug Testing Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
• 7.4. Alcohol
  • 7.4.1. Alcohol market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Cannabis/Marijuana
  • 7.5.1. Cannabis/marijuana market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Cocaine
  • 7.6.1. Cocaine market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Opioids
  • 7.7.1. Opioids testing market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Amphetamine & Methamphetamine
  • 7.8.1. Amphetamine & methamphetamine market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. LSD
  • 7.9.1. LSD market estimates and forecasts 2021 to 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. U.S. Employer and Workplace Drug Testing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Employer and Workplace Drug Testing Market End Use Movement Analysis
• 8.3. U.S. Employer and Workplace Drug Testing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. IT/Finance
  • 8.4.1. IT/finance market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Manufacturing
  • 8.5.1. Manufacturing market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Transportation
  • 8.6.1. Transportation market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Construction
  • 8.7.1. Construction market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Retail and Hospitality
  • 8.8.1. Retail and hospitality market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. Healthcare
  • 8.9.1. Healthcare market estimates and forecasts 2021 to 2033 (USD Million)
• 8.10. Education
  • 8.10.1. Education surgical centers market estimates and forecasts 2021 to 2033 (USD Million)
• 8.11. Other Professional Services
  • 8.11.1. Other Professional Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. List of Key Certification Providers/Scheme Owners
• 9.5. Company Profiles/Listing
  • 9.5.1. First Advantage
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Laboratory Corporation of America Holdings (Labcorp)
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Dragerwerk AG & Co. KGaA
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Bio-Rad Laboratories, Inc.
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Abbott
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Clinical Reference Laboratory Inc.
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Quest Diagnostics
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Cordant Health Solutions
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. DISA Global Solutions
    • 9.5.9.1. Company overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. HireRight, LLC
    • 9.5.10.1. Company overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives
  • 9.5.11. OraSure Technologies, Inc.
    • 9.5.11.1. Company overview
    • 9.5.11.2. Financial performance
    • 9.5.11.3. Product benchmarking
    • 9.5.11.4. Strategic initiatives
  • 9.5.12. Psychemedics Corporation
    • 9.5.12.1. Company overview
    • 9.5.12.2. Financial performance
    • 9.5.12.3. Product benchmarking
    • 9.5.12.4. Strategic initiatives
  • 9.5.13. Omega Laboratories
    • 9.5.13.1. Company overview
    • 9.5.13.2. Financial performance
    • 9.5.13.3. Product benchmarking
    • 9.5.13.4. Strategic initiatives